Skip to content
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
featured-image

Press Release

RapidAI Applauded by Frost & Sullivan for Delivering Quality Care Quickly and Securely With Its RapidAI Platform

RapidAI Applauded by Frost & Sullivan for Delivering Quality Care Quickly and Securely With Its RapidAI Platform SAN ANTONIO, TX. – September 12, 2022 – Frost & Sullivan recently analyzed the artificial intelligence (AI) algorithms for the stroke market, and, based on its assessment results, recognizes RapidAI with the 2022 Global Technology Innovation Leadership Award. The company is a leading provider of advanced imaging for stroke. It is a pioneer in AI-based treatment for vascular and neurovascular conditions and offers innovative solutions for more stroke diagnosis modalities than any other company in the space. RapidAI’s world-class subject matter experts developed advanced cerebrovascular imaging and workflow solutions over the last decade. The company refined its holistic approach to care for life-threatening neurovascular and vascular conditions, continuously building its comprehensive software platform to bridge the care gaps.
featured-image

Press Release

RapidAI Receives FDA Clearance for Rapid Hyperdensity

RapidAI announced it has received FDA clearance for Rapid Hyperdensity, the newest addition to the RapidAI platform San Mateo, Calif. — July 21 , 2022 — RapidAI , the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA clearance for Rapid Hyperdensity , the newest addition to the RapidAI platform. The tool empowers physicians to quickly assess the severity of injury in patients with acute neuro conditions such as traumatic brain injury and brain hemorrhages – allowing for better and faster patient care decisions. Powered by AI, Rapid Hyperdensity uses non-contrast CT scans to quickly assess the volume of hyperdense tissue in the brain to help physicians identify the extent of an intracerebral hemorrhage which is crucial for patient treatment decisions. For hospitals and mobile stroke units on the front lines of patient assessment, Rapid Hyperdensity provides additional contextual data to help physicians make more informed triage and transfer decisions–getting patients to the right place more efficiently. “Rapid Hyperdensity helps physicians make the first of many critical decisions involved in head trauma and hemorrhagic stroke protocol. As the only comprehensive neurovascular decision support platform to offer this functionality, RapidAI aims to alleviate the enormous pressure of determining the best next course of action , ” said Karim Karti, CEO of RapidAI. “This FDA clearance is a symbol of RapidAI’s ongoing commitment to push the boundaries of neurovascular care, while designing every product with physicians first in mind.” The key benefits of Rapid Hyperdensity include: Automated detection of intracranial hyperdensities >1ml Quick identification of hyperdense volumes to improve hemorrhage management Fast results that can be viewed via the Rapid mobile app, PACS/Workstation, or email "As a neurosurgeon who treats many patients with intracranial hemorrhage (ICH), I am very excited for the recently approved Rapid Hyperdensity product that builds on the well-established RapidAI stroke platform,” said Dr. Alejandro M. Spiotta, director of the Neuroendovascular Surgery Division at the Medical University of South Carolina. “Detection of ICH via AI can save lives by helping to speed up diagnosis and accelerate transfer to the best physician and hospital that can take care of the patient. With the addition of automatic hyperdense volume measurement, physicians can more easily track volume over time and help quickly identify which patients may require an intervention. This is an exciting time for those of us treating ICH." To learn more about how RapidAI is transforming stroke care, please visit: https://www.rapidai.com/stroke About RapidAI RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Empowering physicians to make faster decisions for better patient outcomes, RapidAI is leading the next evolution of clinical decision-making and patient workflow. Based on intelligence gained from over 5 million scans in more than 2,000 hospitals in over 60 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI – where AI meets patient care.
featured-image

Press Release

RapidAI Receives FDA 510(k) Clearance for Pulmonary Embolism Triage & Notification

RapidAI announced that it has received FDA 510(k) clearance for its Rapid PE Triage & Notification product for fast identification and communication of suspected central pulmonary embolism. San Mateo, Calif. — May 24 , 2022 — RapidAI , the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, announced today that it has received FDA 510(k) clearance for its Rapid PE Triage & Notification product for fast identification and communication of suspected central pulmonary embolism — further strengthening RapidAI’s industry-leading clinical AI platform. New research shows that death rates for pulmonary embolism have been on the rise over the last decade , with the biggest increase among people under 65. For those who experience and survive a PE incident, one-third will have a recurrence within 10 years . Increasing access to clinically validated technology will be key to helping hospitals more efficiently coordinate care, make accurate diagnoses in a timely manner, and get PE patients to treatment faster, leading to better outcomes. “Building on our expertise in stroke, we’re confident this technology will help modernize PE care and meaningfully improve patient outcomes,” said Karim Karti, CEO of RapidAI. “Our goal is to build solutions that address the specific challenges associated with treating various conditions, as well as the communication and workflow issues faced by hospitals globally. From stroke to aneurysm to PE, we’re proud of how much RapidAI has grown and are excited to continue to redefine the patient care journey.” Rapid PE Triage & Notification, in conjunction with Rapid Workflow for PE , will enable care teams to more easily manage the entire patient care journey, from the moment a suspected PE patient is identified to diagnosis and through treatment. By automatically identifying a suspected pulmonary embolism and delivering real-time notifications to physicians, patients can be triaged faster and care teams aligned more quickly, reducing overall time to treatment. “I’m excited to see first-hand how artificial intelligence will transform the way we triage and manage PE, a historically complicated process involving a diverse care team,” said Dr. Jimmy Kerrigan, an Interventional Cardiologist at Ascension St. Thomas Heart. “After seeing what RapidAI technology has done for stroke, I’m optimistic about its potential to optimize our care for patients and to hopefully improve patient outcomes.” Join us at SIR’s 2022 Annual Scientific Meeting , Booth #346, to learn more about RapidAI clinically-validated solutions, and see a product demonstration of Rapid PE. About RapidAI RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Empowering physicians to make faster decisions for better patient outcomes, RapidAI is leading the next evolution of clinical decision-making and patient workflow. Based on intelligence gained from over 5 million scans in more than 2,000 hospitals in over 60 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI – where AI meets patient care.
featured-image

Press Release

RapidAI Announces Amit Phadnis as New Chief Innovation and Technology Officer

Former GE Healthcare Chief Digital Officer joins group of new leaders spearheading RapidAI’s product innovation; advancing patient care for Pulmonary Embolism, Aneurysm and Stroke globally San Mateo, Calif. — April 6, 2022 — RapidAI , the global leader in neurovascular and vascular imaging driving the next evolution of clinical decision making and patient workflow, today announced Amit Phadnis, former GE Officer and Chief Digital Officer of GE Healthcare, as the company’s new Chief Innovation and Technology Officer. “We are thrilled to have Amit join us at RapidAI as we continue to advance our platform and suite of products to provide better care for patients around the world,” said Karim Karti, CEO of RapidAI. “His vast experience in technology, artificial intelligence, and clinical imaging will serve the team well as we deliver the future of clinical technology for life-threatening diseases.” Amit joins RapidAI with 30 years of experience in leading global product teams. In his role at GE, Amit was responsible for driving the company’s digital and AI strategy, as well as GE Healthcare’s complete digital portfolio, including enterprise imaging solutions, Clinical Command Centers and consulting solutions. With his global digital team, Amit enabled GE’s vision for precision health by creating the industry-leading Edison platform and its cloud, edge, device software infrastructure, data strategy, SaaS enablement, artificial intelligence, and analytics capabilities. Prior to GE, Amit was with Cisco Systems, where he was the India Site Leader and Senior Vice President of Engineering for the Core Software Group, leading product development activities across the routing, switching and wireless areas. Amit has also previously held leadership roles at Motorola, Tata Elxsi, Silicon Automation Systems, and C-DOT. He earned his master’s degree in electronics and communication from the Indian Institute of Science. “I look forward to working with the talented technologists, engineers, and sales leaders at RapidAI, to advance our artificial intelligence platform and meaningfully improve physician workflow and patient outcomes,” said Phadnis. “I was drawn to RapidAI because of its unique suite of products and incredible leadership in the industry. I am grateful for the opportunity to bring my experience to the team and continue to develop technology that pushes the boundaries of care.” As the Chief Innovation and Technology Officer at RapidAI, Amit will oversee the R&D, Engineering and Technology organizations, driving the advancement of the RapidAI comprehensive AI and Workflow Platform for neurovascular and vascular disease care and beyond. RapidAI’s platform leverages AI to create enhanced, high-quality images from NCCT, CTA, CTP and MRI diffusion and perfusion data, which are available to physicians on web and mobile devices. The technology helps physicians make expedient diagnoses and treatment and transfer decisions, and allows for more streamlined communication and coordination of the patient journey. Though its foundations are in the treatment of stroke, RapidAI’s technology has been evolved to apply to several other disease states, with continued advancements to come in the future. In August, RapidAI reached more than 4 million scans on its platform – the most clinically advanced in the industry.
featured-image

Press Release

RapidAI Announces Karim Karti as New CEO

Former GE Healthcare Imaging and iRhythm leader joins pioneers in clinical decision making and patient care coordination San Mateo, Calif. — January 31, 2022 — RapidAI, the global leader in neurovascular and vascular imaging driving the next evolution of clinical decision making and patient workflow, today announced Karim Karti, former President and CEO of GE Healthcare Imaging, as the company’s Chief Executive Officer (CEO). “Karim’s tremendous global experience in healthcare technology and digital health makes him an ideal fit for RapidAI. He has a proven track record in driving commercial success, product expansion and global scale. RapidAI is at a very exciting time in our history as we are scaling the company and substantially expanding our product and global footprint. I’m confident Karim will help ensure our continued growth as the worldwide leader in clinical decision making and patient workflow technology,” said Dr. Greg Albers, Chairman and Co-founder of RapidAI. “RapidAI’s unparalleled clinical validation combined with Karim’s thoughtful approach to business growth will ensure that we continue to support hospitals, physicians, and millions of patients as we advance the treatment of neurovascular diseases, as well as other critical medical disorders.” Karim Karti comes to RapidAI with more than 25 years of experience in the medical technology industry and a demonstrated ability of growing companies and helping them achieve key milestones. He served as Chief Operating Officer at iRhythm Technologies, a cardiac monitoring and AI digital health company. During his tenure, Karim doubled iRhythm’s revenues in 18 months while successfully launching several new breakthrough AI products. Karim also serves as Chairman of the Board for MedTech Acquisition Corporation and is a Director of Rockley Photonics. Notably, Karim spent over 22 years at General Electric, where he worked as President and CEO of GE Healthcare Korea, before being tapped as President and CEO of Emerging Markets, and subsequently Global Chief Marketing Officer for the entire $20B GE Healthcare division. Karim was appointed President and CEO of GE Healthcare Imaging in 2016 and led it to become one of the fastest growing businesses at GE in 2017. In this position, Karim drove significant growth, profitability, and innovation, spearheading a new digital platform and investments in AI-based imaging. “I am proud and humbled to join Dr. Albers, Dr. Roland Bammer, and the whole team at RapidAI in their mission to improve the diagnosis and treatment of life-threatening conditions. As trailblazers in the space, RapidAI has helped to shape the way we diagnose and treat neurovascular and vascular disease and made a meaningful impact in the lives of people around the world,” said Karti. “I look forward to bringing my own experience in imaging, artificial intelligence and digital health to help push the boundaries of clinical technology and patient care even further and continue to save lives. RapidAI has pioneered the field with five key randomized clinical trials, all published in the New England Journal of Medicine, that set a new standard for stroke treatment worldwide and showed the superior approach of the RapidAI solution. RapidAI is the undisputed leader with a presence in over 2000 hospitals and 60 countries, a testament to the value of RapidAI for patients, physicians, hospitals and health systems.” Karim’s leadership philosophy is rooted in open communication and nurturing talent and diversity. He believes in a leadership approach that combines full transparency, teamwork and collaboration with a passion for advancing clinical innovation and helping patients around the world. Karim has a MSc in engineering from Ecole Centrale de Lyon and completed the entrepreneurship program of Ecole Superieure de Commerce de Lyon. He lives with his wife and two daughters in the Bay Area. "I have been extremely impressed by the depth of Karim’s experience, leadership and passion for innovation. I look forward to working with him as we expand the breadth and depth of our product portfolio," said Dr. Roland Bammer, CTO and Co-founder of RapidAI. RapidAI’s platform leverages AI to create enhanced, high-quality images from NCCT, CTA, CTP and MRI diffusion and perfusion data, which are available to physicians through PACS, email, and the Rapid mobile and web apps. The technology helps physicians make expedient diagnoses, treatment and transfer decisions, and allows for more streamlined communication and coordination of the patient journey. Though its foundations are in the treatment of stroke, RapidAI technology has evolved to cover aneurysm and pulmonary embolism, with continued advancements to come. RapidAI has processed more than 4 million scans on its platform – the most clinically advanced in the industry.
featured-image

Press Release

RapidAI Receives TFDA Approval for Commercial Use

Rapid advanced imaging software helps speed up diagnosis, streamline clinical workflows, and improve stroke care for patients in Taiwan 中文 Taipei, TAIWAN — September 23, 2021 — RapidAI, the global leader in neurovascular imaging driving the next evolution of clinical decision making and patient workflow, is pleased to announce that it has received approval from the Taiwan Food and Drug Administration (TFDA) for its Rapid CTA, Rapid CTP, Rapid MRI, and Rapid for Angio products and is now commercially available to hospitals and health systems in Taiwan. It is currently being used in 10+ hospitals in Taiwan and more than 1800 hospitals in over 60 countries. According to the Taiwanese Ministry of Health and Welfare, one in six of the Taiwan population suffer from a stroke at least once in their lifetime, and the cerebrovascular disease is one of top five causes of death in the country, taking an average of 10,000+ lives each year. For patients and their families every second counts when it comes to treatment, as research shows patients can lose nearly 1.9 million neurons every minute in which stroke is yet to be treated. Shortening the diagnosis time for doctors has then become a key for patient's survival after a stroke. The first step of shortening diagnosis and treatment time is streamlining imaging and communications. When a stroke patient arrives to the emergency room, he/she typically undergoes a brain computed tomography, or CT scan, as well as other medical imaging such as a Multimodal CT or MRI to provide sufficient images for doctors to evaluate their condition and decide next steps. With the RapidAI platform, developed by an experienced team of neurologists, radiologists, technologists and entrepreneurs, care teams are able to more easily view CT images, make quicker decisions, and get patients treatment faster. Specifically, Rapid CTP can provide quantitative and color-coded models in just two minutes for doctors to assess salvageable brain tissue quickly. RapidAI can also quickly calculate the number and proportion of salvageable brain tissue and necrotic brain tissue, so doctors can determine whether the patient is still suitable for rt-PA or endovascular thrombectomy. RapidAI also optimizes the medical team’s workflow by enabling doctors to immediately view a patient's status through the Rapid mobile app, share the images with other members of the care team, and discuss the patient’s diagnosis, anytime and from anywhere. “With an easy-to-use interface, Rapid automatically selects ischemic brain images indicated for thrombolysis and/or thrombectomy for the stroke team. The implementation of Rapid has shortened the door-to-recanalization time and helped more patients receive efficient treatments,” said Dr. Nai-Fang Chi, Department of Cerebrovascular, Neuromedicine Center of Taipei Veterans General Hospital. RapidAI is a highly recognized and widely used medical imaging platform worldwide. The 2018 DAWN and DEFUSE 3 studies, which were conducted using Rapid, were the primary research that led the American Heart Association (AHA) and the American Stroke Association (ASA) to update their acute stroke treatment protocols, extending the treatment window for acute stroke patients from 6 to 24 hours. Dr. I-Hui Lee, Director of Department of Neurology and Cerebrovascular in Taipei Veterans General Hospital, shared: "We are happy that Rapid has been approved by Taiwan FDA for clinical applications. We believe this will also help more stroke teams in Taiwan to provide high-quality and efficient treatment for patients."
featured-image

Press Release

LATAM hospitals receive Quality Stroke Care Certification

The exclusive partnership offers certified advanced stroke centers access to the Rapid® artificial intelligence platform for one year as well as exclusive training programs Read the press release in Portuguese Read the press release in Spanish São Paulo — September 20, 2021 — RapidAI, a global leader in cerebral image analysis (neuroimaging) that has revolutionized the stroke treatment workflow and decision-making process, would like to congratulate hospitals Albert Einstein, Hospital das Clínicas de Ribeirão Preto, Hospital Moinhos de Vento and Hospital São José Joinville for their recent certification by the World Stroke Organization (WSO) and the Iberoamerican Society of Cerebrovascular Diseases (SIECV). These institutions were officially certified by the WSO and the Iberoamerican SIECV this Monday following a Board Review after meeting international patient care quality standards. As exclusive neuroimaging partner in the WSO/SIEVC project, RapidAI combines its AI stroke image analysis platform with an exclusive training program for each type of certification to help Latin-American hospitals meet the strict standards for each WSO certification level, which in turn helps improve patient care. “The Certification Program guarantees full access to the tools needed to provide these services, reducing the level of mortality and lesions this devastating disease can cause. Stroke Center representatives can access the platform and self-assess their hospitals. If they are eligible for certification, they then have to submit their documents for prior analysis and then receive an in-person inspection. The results are later assessed by international experts, who award certification,” explained Dr. Sheila Martins, president-elect of the Stroke Centers. Dr. Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of RapidAI, expects the program to continue providing healthcare specialists with the scientific evidence they need on which to base their decisions and adopt clear performance metrics that will create an environment in which quality can continuously improve. “Hospitals are always looking to improve their diagnostic abilities and increase stroke unit efficiency. The Rapid platform can do this more accurately and effectively. We have already seen an improvement in stroke patient outcomes and this has already improved patient quality of life”, he noted. RapidAI is already available in over 1,800 hospitals across 60 countries. It is the most widely used cerebrovascular imaging platform in the world for stroke patient care, research and clinical trials and plans to support certification of more than 100 advanced stroke centers across Latin America next year. “One in four people will have a stroke in their lifetime. Having innovative technology such as the RapidAI makes a real difference when caring for Latin American patients. We are proud to be able to support an increasing number of hospitals that are investing in certification and adopting best practices. We want to support them throughout this benchmark patient care process,” said Renato Cunha, VP of Sales and Operations, LATAM at RapidAI.
featured-image

Press Release

RapidAI Achieves Record Momentum

Leader in neurovascular and vascular imaging analysis gains worldwide momentum with extended NTAP reimbursement, record number of scans, product innovation, new partnerships, and influential board members San Mateo, Calif. — August 19, 2021 — RapidAI, the global leader in neurovascular and vascular imaging driving the next evolution of clinical decision making and patient workflow, today announced record corporate momentum with more than 2.8M scans to date on its platform — the most clinically advanced in the industry. The COVID-19 pandemic has increased providers’ need for technology that brings together previously disconnected care teams. Now in use at more than 1,800 hospitals across 60 countries — including 18 of the top 20 in U.S. News’ 2020-21 Best Hospitals report — hospitals deploying RapidAI are automating workflows and improving communications to enable quicker triage and treatment. “We continue to be laser-focused on bringing advanced solutions to improve patient care,” said Don Listwin, CEO of RapidAI. “As we build significant relationships with our customers and leading organizations, and gain certifications that further validate our platform, we are excited not just about the momentum we have achieved, but also the opportunity to redefine the patient care journey with AI.” As the global leader using AI to combat life-threatening conditions, RapidAI has achieved the following since the start of 2021: Extended NTAP reimbursement - The New Technology Add-on Payment (NTAP) for Rapid LVO was recently renewed based on its demonstrated ability to increase access to care, save time, and improve outcomes. NTAP is an additional Medicare reimbursement that financially assists healthcare organizations when they adopt new technology. Record number of scans – RapidAI has seen substantial growth in the number of scans processed on its platform , reaching more than 2.8M to date. In the first half of 2021 alone , the platform saw nearly 1 million scans from over 500,000 patients around the world, approximately two scans every minute since the start of the year. P roduct innovation – Building on its platform for stroke and aneurysm, which combined, have more FDA clearances than any other company in this space, RapidAI has expanded its portfolio to address prehospital stroke care and pulmonary embolism. Introduced in June, Rapid Workflow for PE , is a product designed to align hospital teams on the treatment of patients suspected of having a pulmonary embolism. The Rapid for Prehospital mobile app, launched in May, helps EMS and hospitals follow a standardized stroke protocol that streamlines data collection and improves collaboration while en route to an appropriate hospital. Impactful global partnerships – The recently l aunched Rapid Workflow for PE is a product of the partnership with Penumbra, Inc. , a global healthcare company focused on innovative therapies to treat ischemic stroke and vascular blood clots. Additionally, RapidAI recently partnered with Stryker in the US to deliver flexible financing solutions, offering RapidAI stroke and aneurysm imaging software with Stryker neurovascular devices. T he company also expanded global partnerships in Latin America , as the exclusive neuroimaging partner for the new Stroke Center Certification Program through a partnership with the World Stroke Organization (WSO) , as well as in Australia , having secured TGA clearance for the Rapid stroke imaging platform and now serving more than 50 hospitals and teleradiology services across the country. Bolstered board membership – RapidAI has also recently added two new board members , Dr. Hadi Saleh, CEO of the CeramTec Group and John Drew, General Partner, TCV.z “It’s critical that healthcare providers have reliable real-time clinical data from the very earliest stages of patient care to make informed decisions and communicate efficiently,” said Alejandro Spiotta, M.D., Medical University of South Carolina Division of Neuroendovascular Surgery Director. “With time being so critical, an advanced platform like RapidAI’s is essential to streamline patient workflow and improve communications across the entire care team.” With many new products on the horizon, RapidAI is poised to continue its growth and lead the way in helping hospitals transform patient care for life-threatening conditions.
featured-image

Press Release

RapidAI Launches Rapid Workflow for Pulmonary Embolism (PE)

Developed in partnership with Penumbra, the solution supports faster team activation to accelerate PE care and drive better patient outcomes San Mateo, Calif. — June 24, 2021 — RapidAI, leading the next evolution of clinical decision making and patient workflow, today announced the availability of Rapid Workflow for PE, a mobile and web-based app designed to align hospital teams on the treatment of patients suspected of having a pulmonary embolism. Pulmonary embolism is a sudden blockage of one or more pulmonary arteries caused by a blood clot. The CDC estimates that as many as 900,000 people could be affected by venous thromboembolism (VTE), which includes PE and deep vein thrombosis, each year in the U.S. PE results in the death of one-third of people who go undiagnosed or untreated, according to the Mayo Clinic. “Rapid Workflow for PE is the next step in our journey to improving patient care,” Don Listwin, CEO of RapidAI, said. “When it comes to acute vascular diseases, time is of the essence. That’s why we’ve created an extensible platform that addresses the specific needs of care teams across vascular and neurovascular conditions, providing these teams with the tools they need to work quickly to save lives.” Rapid Workflow for PE helps hospital teams align, activate and communicate about patient status to administer care faster. More specifically, the solution helps: Reduce time to treatment: Provides access anywhere, anytime to CTPA images and workflow communication tools Improve care coordination: Streamlines communication and accelerates PE team activation Optimize protocols: Collects patient status data that teams can utilize to improve their risk stratification and patient care processes The Rapid Workflow for PE solution is born out of RapidAI’s recent partnership with Penumbra, Inc., a global healthcare company focused on innovative therapies in areas that include ischemic stroke and vascular blood clots. The partnership was established in November 2020, to develop solutions enabling faster clinical decision making for PE diagnosis and procedures. “Pulmonary embolism can be a life-threatening condition and requires swift action to prevent serious complications,” said James F. Benenati, MD, chief medical officer at Penumbra, Inc. “Through our collaboration, we are now able to arm healthcare providers with critical data to make decisions quickly and coordinate care more efficiently. It is exciting to see our shared vision to innovate pulmonary care come to life and further move the PE field forward with this latest advancement.” “Since the inception of our PERT team, we have been looking for ways to leverage advanced technologies to improve patient outcomes. Collaborating with RapidAI has allowed us to utilize their platform, first used to streamline the workflow in stroke, and bring this technology into the pulmonary embolism space. RapidAI will allow us to advance diagnostics, treatment algorithms, and communications across multiple providers and facilities,” said Dr. Jay Mathews, Director, Cardiac Catheterization Lab, Structural Heart, and PERT at Manatee Memorial Hospital. For more information or to get started using Rapid Workflow for PE, please visit: https://www.rapidai.com/rapid-workflow-for-pe
1 2 3 4 5